Motor pathway excitability in ATP13A2 mutation carriers: A transcranial magnetic stimulation study

Parkinsonism and Related Disorders

Volumn 18, Issue 5, 2012, Pages 590-594

  Zittel, S ^a   Kroeger, J ^a   van der Vegt, J P M ^b,c,d   Siebner, H R ^b,d   Bruggemann N ^e   Ramirez, A ^e,f   Behrens, M I ^g   Gerloff, C ^a   Baumer T ^a   Klein, C ^e   Munchau A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d Mental Health Services CPH   (Denmark)

^e UNIVERSITY OF LÜBECK   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY OF CHILE   (Chile)

Author keywords

ATP13A2 mutation carriers; Contralateral silent period; Ipsilateral silent period; Transcranial magnetic stimulation

Indexed keywords

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; ATP13A2 GENE; BRAIN CORTEX; CHILEAN; CLINICAL ARTICLE; CONTRALATERAL SILENT PERIOD; CONTROLLED STUDY; ETHNICITY; EVOKED MUSCLE RESPONSE; FACILITATION; FEMALE; GENE; GENE MUTATION; HEMISPHERE; HETEROZYGOTE; HUMAN; INTERHEMISPHERIC INHIBITION; INTRACORTICAL FACILITATION; IPSILATERAL SILENT PERIOD; KUFOR RAKEB SYNDROME; MALE; MOTOR SYSTEM; NERVE CELL INHIBITION; NERVE DEGENERATION; NERVE EXCITABILITY; NERVOUS SYSTEM PARAMETERS; PRIORITY JOURNAL; SHORT INTERVAL INTRACORTICAL INHIBITION; SHORT LATENCY AFFERENT INHIBITION; TRANSCRANIAL MAGNETIC STIMULATION;

AGED; ANALYSIS OF VARIANCE; CHILE; EFFERENT PATHWAYS; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FAMILY HEALTH; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MUTATION; NEURAL INHIBITION; PARKINSONIAN DISORDERS; PROTON-TRANSLOCATING ATPASES; REACTION TIME; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84861189690     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.10.020     Document Type: Article

References (20)

1. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006, 38:1184-1191.
2. Klein C., Lohmann-Hedrich K., Rogaeva E., Schlossmacher M.G., Lang A.E. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007, 6:652-662.
3. Priori A., Berardelli A., Inghilleri M., Accornero N., Manfredi M. Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism. Brain 1994, 117:317-323.
4. Ridding M.C., Inzelberg R., Rothwell J.C. Changes in excitability of motor cortical circuitry in patients with Parkinson's disease. Ann Neurol 1995, 37:181-188.
5. Sailer A., Molnar G.F., Paradiso G., Gunraj C.A., Lang A.E., Chen R. Short and long latency afferent inhibition in Parkinson's disease. Brain 2003, 126:1883-1894.
6. Baumer T., Pramstaller P.P., Siebner H.R., Schippling S., Hagenah J., Peller M., et al. Sensorimotor integration is abnormal in asymptomatic Parkin mutation carriers: a TMS study. Neurology 2007, 69:1976-1981.
7. Schneider S.A., Talelli P., Cheeran B.J., Khan N.L., Wood N.W., Rothwell J.C., et al. Motor cortical physiology in patients and asymptomatic carriers of parkin gene mutations. Mov Disord 2008, 23:1812-1819.
8. De Rosa A., Volpe G., Marcantonio L., Santoro L., Brice A., Filla A., et al. Neurophysiological evidence of corticospinal tract abnormality in patients with Parkin mutations. J Neurol 2006, 253:275-279.
9. Bruggemann N., Hagenah J., Reetz K., Schmidt A., Kasten M., Buchmann I., et al. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010, 67:1357-1363.
10. Ebersbach G., Baas H., Csoti I., Mungersdorf M., Deuschl G. Scales in Parkinson's disease. J Neurol 2006, 253:32-35.
11. Kujirai T., Caramia M.D., Rothwell J.C., Day B.L., Thompson P.D., Ferbert A., et al. Corticocortical inhibition in human motor cortex. J Physiol 1993, 471:501-519.
12. MacKinnon C.D., Gilley E.A., Weis-McNulty A., Simuni T. Pathways mediating abnormal intracortical inhibition in Parkinson's disease. Ann Neurol 2005, 58:516-524.
13. Siebner H.R., Mentschel C., Auer C., Lehner C., Conrad B. Repetitive transcranial magnetic stimulation causes a short-term increase in the duration of the cortical silent period in patients with Parkinson's disease. Neurosci Lett 2000, 284:147-150.
14. Baumer T., Hidding U., Hamel W., Buhmann C., Moll C.K., Gerloff C., et al. Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson's disease. Mov Disord 2009, 24:672-676.
15. Kuhn A.A., Grosse P., Holtz K., Brown P., Meyer B.U., Kupsch A. Patterns of abnormal motor cortex excitability in atypical parkinsonian syndromes. Clin Neurophysiol 2004, 115:1786-1795.
16. Giovannelli F., Borgheresi A., Balestrieri F., Zaccara G., Viggiano M.P., Cincotta M., et al. Modulation of interhemispheric inhibition by volitional motor activity: an ipsilateral silent period study. J Physiol 2009, 587:5393-5410.
17. Hubers A., Orekhov Y., Ziemann U. Interhemispheric motor inhibition: its role in controlling electromyographic mirror activity. Eur J Neurosci 2008, 28:364-371.
18. Li J.Y., Espay A.J., Gunraj C.A., Pal P.K., Cunic D.I., Lang A.E., et al. Interhemispheric and ipsilateral connections in Parkinson's disease: relation to mirror movements. Mov Disord 2007, 22:813-821.
19. Pal P.K., Gunraj C.A., Li J.Y., Lang A.E., Chen R. Reduced intracortical and interhemispheric inhibitions in corticobasal syndrome. J Clin Neurophysiol 2008, 25:304-312.
20. Beck S., Shamim E.A., Richardson S.P., Schubert M., Hallett M. Inter-hemispheric inhibition is impaired in mirror dystonia. Eur J Neurosci 2009, 29:1634-1640.